A key example is the FDA-approved PSMA-targeting tracer, [68Ga]Ga-PSMA-11, for imaging of metastatic castration-resistant prostate cancer, showing a higher prognostic value compared to [18F]FDG-PET to stratify patients for PSMA-targeted therapy [99]. This evidence concerns the gene FOLH1 and prostate cancer.